(photo/network screenshot)
[Australia Network compiled report] The Australian government has signed four separate agreements on the supply of new crown vaccines, provided that these vaccines are proven to be safe and effective.
The Seventh News reported on the 13th that the Australian government has ordered four new crown vaccines, a total of 134.8 million doses, namely Pfizer/BioNTech, AstraZeneca/ Oxford University , Novavax (Novavax), and COVAX Facility. The Australian government previously set a goal to get the first batch of vaccines by the end of March, but has now received new recommendations to start vaccination since early March.
In response to this, Federal Health Minister Greg Hunt said: "With the provision of data and regulatory guidance, we have gradually advanced the vaccination program from mid-year to the second quarter, and then to the end of March, and now it is early March." The Australian government also hopes to start vaccinating about 80,000 people every week, and then expand the scale, and get everyone vaccinated by October.
The following are four new coronavirus vaccines currently provided by Australia:
(1) Pfizer/BioNTech vaccine
Australia will be one of the first countries to have the conditions to approve the Pfizer vaccine, after Australia decided to advance the launch of the vaccine to mid-February. In addition, the Australian Drug Administration also expects to obtain all the required data from vaccine developer Pfizer in mid-January and will approve the vaccine by the end of January.
Prince Morrison (Scott Morrison) said that it will take about two weeks for Pfizer's global agreement to complete approval. It is reported that Pfizer's vaccine is more difficult to control than AstraZeneca's vaccine because it must be stored and transported at a temperature of minus 70 degrees Celsius, which can be kept in the refrigerator. The federal government has advanced the launch of the Pfizer vaccine until early March.
(2) AstraZeneca/Oxford University vaccine
The new crown vaccine jointly developed by AstraZeneca and Oxford University is the second major vaccine candidate in Australia. Australia has currently obtained nearly 54 million doses of AstraZeneca vaccine, of which 50 million were produced by CSL in , Victoria, and the company has begun to produce vaccines.
In January this year, the UK became the first country in the world to start using the AstraZeneca vaccine. The AstraZeneca vaccine is also expected to be put into use in Australia by the end of March.
(3)Novavax (Novavax) vaccine
The vaccine developed by Novavax (Novavax) in the United States is undergoing late-stage trials, and the data will be released in the first half of 2021. The company is expected to start a large-scale trial in the United States in January. Currently, phase 1/2 clinical trials are being conducted in Australia and the United States, while large-scale phase 3 clinical trials are being conducted in the United Kingdom, involving a total of 15,000 volunteers. The vaccine is being tested in different populations, such as those infected with HIV and other chronic diseases, ranging from 18 to 84 years old. Once the Novavax vaccine is approved successfully, Australia is expected to receive 51 million doses of vaccine in 2021, although the specific implementation date has not been determined.
(4) COVAX Facility vaccine
The Australian government has invested a lot of money in COVAX Facility as part of a global effort to support rapid and equitable access to the COVID-19 vaccine. At present, 188 countries around the world have joined the COVAX Facility vaccine development program. Participation in countries such as Australia also means the agency can invest in a variety of possible COVID-19 vaccines and support vaccine manufacturers. It is reported that Covax plans to mobilize 2 billion doses of vaccines worldwide by the end of 2021 to deal with the acute phase of the epidemic. (Compiled by Wei Wei)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-